PRKAA2 and metabolic dysfunction-associated steatohepatitis: In the future, it will be interesting to test metformin against preventative and intervention dosing of a specific and direct AMPK activator like PXL770 (25) in cell-specific AMPK null models to fully dissect the cell type and signaling that are important during the onset and progression of NASH.